GRANT ANNOUNCENT! The Austrian startup Neurolentech, led by Carsten Pfeffer, PhD and co-founded by Gaia Novarino, PhD, Professor of Neuroscience at Institute of Science and Technology Austria (IST Austria), will receive $224,064 toward research projects that will model SLC13A5 Epilepsy in patient-derived SLC13A5 cells.
This grant to Neurolentech will continue studies started in 2019 by Dr. Novarino at IST Austria.
“We are deeply honored to extend our work on 2D neuronal cultures of SLC13A5 patients. Kim Nye and TESS Research Foundation are role models in the fight for bringing relief to patients with severe neurodevelopmental disorders. Our initial analysis of the co-cultures is both scientifically exciting and promising for deciphering novel treatments,” said Dr. Novarino.
Adds Dr. Pfeffer, “A cellular disorder model with a disorder-associated phenotype is a very valuable tool in developing, testing, and validating therapeutic approaches. We feel privileged to work with TESS Research Foundation towards drug development for SLC13A5 Epilepsy and are excited to advance the development of the SLC13A5 disorder model and study its effects, consequences and utility.”
Adds TESS Scientific Director, Tanya Brown, PhD, “We are thrilled to continue working with Dr. Novarino, Dr. Pfeffer, and their team at Neurolentech. They truly understand the urgency of our families’ need for better treatments and cures.”
To learn more about Neurolentech, watch this short video.
‌
‌
‌
‌
